SCZD3
MCID: SCH080
MIFTS: 37

Schizophrenia 3 (SCZD3)

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Schizophrenia 3

MalaCards integrated aliases for Schizophrenia 3:

Name: Schizophrenia 3 56 12 15 71
Schizophrenia Susceptibility Locus, Chromosome 6-Related 56 13
Sczd3 56 12
Schizophrenia 3 with or Without an Affective Disorder 56

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant susceptibility (6p23)


HPO:

31
schizophrenia 3:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0070079
OMIM 56 600511
MedGen 41 C1838069
UMLS 71 C1838069

Summaries for Schizophrenia 3

Disease Ontology : 12 A schizophrenia that has material basis in an autosomal dominant mutation of SCZD3 on chromosome 6p23.

MalaCards based summary : Schizophrenia 3, also known as schizophrenia susceptibility locus, chromosome 6-related, is related to schizophrenia and autoimmune polyendocrine syndrome type 1. An important gene associated with Schizophrenia 3 is SCZD3 (Schizophrenia Disorder 3), and among its related pathways/superpathways are Serotonergic synapse and Tryptophan metabolism. The drugs Ethanol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex, and related phenotypes are abnormality of the nervous system and schizophrenia

More information from OMIM: 600511

Related Diseases for Schizophrenia 3

Graphical network of the top 20 diseases related to Schizophrenia 3:



Diseases related to Schizophrenia 3

Symptoms & Phenotypes for Schizophrenia 3

Human phenotypes related to Schizophrenia 3:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 31 HP:0000707
2 schizophrenia 31 HP:0100753

Symptoms via clinical synopsis from OMIM:

56
Neuro:
schizophrenia

Clinical features from OMIM:

600511

Drugs & Therapeutics for Schizophrenia 3

Drugs for Schizophrenia 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
4
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
5 Tranquilizing Agents Phase 4
6 Antipsychotic Agents Phase 4
7 Dopamine Antagonists Phase 4
8 Paliperidone Palmitate Phase 4
9 Serotonin Agents Phase 4
10 Central Nervous System Depressants Phase 4
11 Dopamine D2 Receptor Antagonists Phase 4
12 Serotonin Antagonists Phase 4
13 Serotonin 5-HT2 Receptor Antagonists Phase 4
14 Dopamine Agents Phase 4
15 Narcotics Phase 4
16 Cytochrome P-450 Enzyme Inhibitors Phase 4
17 Psychotropic Drugs Phase 4
18 Narcotic Antagonists Phase 4
19 Antidepressive Agents Phase 4
20 Dopamine Uptake Inhibitors Phase 4
21 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
22 Bupropion hydrochloride, naltrexone hydrochoride drug combination Phase 4
23
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
24
Rimonabant Approved, Investigational Phase 2 168273-06-1, 158681-13-1 104850
25 3-(2,4-dimethoxybenzylidene)anabaseine Phase 2
26 Neurotransmitter Agents Phase 2
27 Anti-Obesity Agents Phase 2
28 Hormone Antagonists Phase 2
29 Hormones Phase 2
30
leucovorin Approved 58-05-9 6006 143
31
Methylcobalamin Approved, Investigational 13422-55-4
32
Hydroxocobalamin Approved 13422-51-0 11953898 15589840
33
Nicotinamide Approved, Investigational 98-92-0 936
34
Guaifenesin Approved, Investigational, Vet_approved 93-14-1 3516
35
Cyanocobalamin Approved, Nutraceutical 68-19-9 44176380
36
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
37
Niacin Approved, Investigational, Nutraceutical 59-67-6 938
38
Cobalamin Experimental 13408-78-1 6857388
39 Trace Elements
40 Hematinics
41 Vitamin B 12
42 Vitamins
43 Vitamin B Complex
44 Nutrients
45 Vitamin B12
46 Vitamin B9
47 Folate
48 Micronutrients
49 Vitamin B3
50 Nicotinic Acids

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 A Study on the Efficacy, Pharmacokinetics and Adverse Effects of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
2 Effect of Naltrexone and Bupropion Combination on Weight Loss and Smoking Cessation in Obese, Cigarette-smoking Patients With Schizophrenia Completed NCT02736474 Phase 4 Naltrexone;Placebo Naltrexone;Bupropion;Placebo Bupropion
3 A Double-blind Placebo Controlled Trial the Comparison of Effectiveness of Repetitive TMS and iTBS on Negative Symptoms and Cognition in Patients With Schizophrenia Unknown status NCT01315587 Phase 2
4 Phase 2 Trial of 3-2,4 Dimethoxybenzylidene Anabaseine in Schizophrenia Unknown status NCT00100165 Phase 2 3-2,4 dimethoxybenzylidene 75 or 150 mg bid;Placebo
5 A Culturally Based Family Therapy for Schizophrenia Completed NCT00356317 Phase 2
6 The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia Terminated NCT00547118 Phase 2 Rimonabant;Placebo
7 9 wk, Randomized, 2-blind, Placebo-controlled, 2X2 Cross-over Phase 1 Study of 25 mg of Scelectium Tortuosum (as Zembrin®) in Aged Normals to Find Effects on Mental, Emotional and Cognitive Safety Measures and Cytokines. Completed NCT01805518 Phase 1
8 Relationships of One-carbon Cycle Pathway With Psychopathology and Metabolic Abnormalities in Patients With Schizophrenia and Potential Intervention Strategy With Folic Acid and Vitamin B12 Unknown status NCT02916121
9 A Randomised, Double-blind, Cross-over, Placebo Controlled, Adjunctive-treatment of L-arginine Added to Treatment-as-usual (TAU) in Schizophrenia Completed NCT00718510 L-Arginine
10 Specific Cognitive Remediation for Schizophrenia (RECOS) and Sheltered Employment: a Multicentre Controlled Randomized Trial. Completed NCT01891929
11 Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects Completed NCT02575209
12 Molecular Genetic Study of Schizophrenia: Parent-Offspring Trios Completed NCT00155506
13 Shiatsu Adjuvant Therapy for Hospitalized Psychiatric Patients: an Open Pilot Study Completed NCT00425399
14 A Positional Cloning Study on Schizophrenia Completed NCT00155649
15 A 12-weeks Study to Evaluate the Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of First Episode Schizophrenia Recruiting NCT03379597 Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)
16 A Study of the Aggressive Acts Among Patients With Schizophrenia Suspended NCT00172497
17 A Study on Etiological Factors of Schizophrenia Terminated NCT00155636

Search NIH Clinical Center for Schizophrenia 3

Genetic Tests for Schizophrenia 3

Anatomical Context for Schizophrenia 3

MalaCards organs/tissues related to Schizophrenia 3:

40
Brain, Cortex, Prefrontal Cortex, Eye, Cerebellum, Thyroid, Temporal Lobe

Publications for Schizophrenia 3

Articles related to Schizophrenia 3:

(show top 50) (show all 132)
# Title Authors PMID Year
1
Schizophrenia risk from complex variation of complement component 4. 56
26814963 2016
2
Common variants conferring risk of schizophrenia. 56
19571808 2009
3
Common variants on chromosome 6p22.1 are associated with schizophrenia. 56
19571809 2009
4
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. 56
19571811 2009
5
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. 56
18583979 2008
6
Assessment of cumulative evidence on genetic associations: interim guidelines. 56
17898028 2008
7
Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. 56
17921251 2007
8
Analysis of high-resolution HapMap of DTNBP1 (Dysbindin) suggests no consistency between reported common variant associations and schizophrenia. 56
17033966 2006
9
Dysbindin genotype and negative symptoms in schizophrenia. 56
16513878 2006
10
Identifying potential risk haplotypes for schizophrenia at the DTNBP1 locus in Han Chinese and Scottish populations. 56
16044171 2005
11
Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit. 56
16080121 2005
12
Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. 56
15917270 2005
13
Association of the DTNBP1 locus with schizophrenia in a U.S. population. 56
15362017 2004
14
Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. 56
15345706 2004
15
Linkage disequlibrium in the DTNBP1 (dysbindin) gene region and on chromosome 1p36 among psychotic patients from a genetic isolate in Israel: findings from identity by descent haplotype sharing analysis. 56
15211634 2004
16
Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1). 56
15066891 2004
17
The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. 56
14618545 2003
18
Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. 56
12474144 2003
19
Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. 56
12098102 2002
20
Genome-wide scans of three independent sets of 90 Irish multiplex schizophrenia families and follow-up of selected regions in all families provides evidence for multiple susceptibility genes. 56
12140777 2002
21
Association analysis of NOTCH4 loci in schizophrenia using family and population-based controls. 56
11381257 2001
22
Failure to confirm NOTCH4 association with schizophrenia in a large population-based sample from Scotland. 56
11381258 2001
23
The NOTCH4 locus is associated with susceptibility to schizophrenia. 56
10932176 2000
24
NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. 56
9674972 1998
25
Use of a quantitative trait to map a locus associated with severity of positive symptoms in familial schizophrenia to chromosome 6p. 56
9399881 1997
26
Fine mapping of 39 ESTs on human chromosome 6p23-p25. 56
9417921 1997
27
6p24-22 region and major psychoses in the Eastern Quebec population. Le Groupe IREP. 56
9184316 1997
28
Linkage study of chromosome 6p in sib-pairs with schizophrenia. 56
9184317 1997
29
Additional support for schizophrenia linkage on chromosomes 6 and 8: a multicenter study. Schizophrenia Linkage Collaborative Group for Chromosomes 3, 6 and 8. 56
8950417 1996
30
Linkage analyses of schizophrenia to chromosome 6p24-p22: an attempt to replicate. 56
8950418 1996
31
Evidence of linkage disequilibrium between schizophrenia and the SCa1 CAG repeat on chromosome 6p23. 56
8751875 1996
32
Irish study on high-density schizophrenia families: field methods and power to detect linkage. 56
8723045 1996
33
A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity. 56
7581452 1995
34
An international two-stage genome-wide search for schizophrenia susceptibility genes. 56
7581457 1995
35
Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib-pair linkage analysis. 56
7581458 1995
36
Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. 56
7581446 1995
37
Dispute splits schizophrenia study. 56
7754362 1995
38
Evidence for a susceptibility locus for schizophrenia on chromosome 6pter-p22. 56
7647789 1995
39
Functioning in community-dwelling patients with schizophrenia spectrum disorders in rural Greece. 61
31692402 2019
40
Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS). 61
31196736 2019
41
Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. 61
30116031 2019
42
The relationship between the alterations in metabolite levels in the dorsolateral prefrontal cortex and clinical symptoms of patients with first-episode schizophrenia: a one year follow-up study. 61
30728911 2019
43
Performance of International Medical Students In psychosocial medicine. 61
28693486 2017
44
[Evolution of the schizophrenic deficit concept]. 61
29053114 2017
45
What are the top 10 physical activity research questions in schizophrenia? 61
26728764 2016
46
The 40-Hz Auditory Steady-State Response in Patients With Schizophrenia: A Meta-analysis. 61
27732692 2016
47
Bilingualism and schizophrenia. 61
27354960 2016
48
Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction. 61
26320195 2016
49
More Consistently Altered Connectivity Patterns for Cerebellum and Medial Temporal Lobes than for Amygdala and Striatum in Schizophrenia. 61
26924973 2016
50
Polymorphisms in MicroRNA Genes And Genes Involving in NMDAR Signaling and Schizophrenia: A Case-Control Study in Chinese Han Population. 61
26257337 2015

Variations for Schizophrenia 3

Expression for Schizophrenia 3

Search GEO for disease gene expression data for Schizophrenia 3.

Pathways for Schizophrenia 3

GO Terms for Schizophrenia 3

Biological processes related to Schizophrenia 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 circadian rhythm GO:0007623 9.26 TPH2 TPH1
2 aromatic amino acid family metabolic process GO:0009072 9.16 TPH2 TPH1
3 indolalkylamine biosynthetic process GO:0046219 8.96 TPH2 TPH1
4 serotonin biosynthetic process GO:0042427 8.62 TPH2 TPH1

Molecular functions related to Schizophrenia 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.16 TPH2 TPH1
2 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 8.96 TPH2 TPH1
3 tryptophan 5-monooxygenase activity GO:0004510 8.62 TPH2 TPH1

Sources for Schizophrenia 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....